Compare ABVE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVE | DTIL |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | Canada | United States |
| Employees | N/A | 68 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 136.0M |
| IPO Year | N/A | 2019 |
| Metric | ABVE | DTIL |
|---|---|---|
| Price | $0.87 | $5.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 2.2M | 337.4K |
| Earning Date | 07-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $3.53 |
| 52 Week High | $6.56 | $8.82 |
| Indicator | ABVE | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 52.65 |
| Support Level | $0.61 | $3.96 |
| Resistance Level | $2.08 | $7.59 |
| Average True Range (ATR) | 0.16 | 0.58 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 38.97 | 16.57 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).